Mode
Text Size
Log in / Sign up
N/A N=8 Treatment

The Feasibility of Engage Therapy With Video Support for Homebound Older Adults

Depression

Enrolled (actual)
8
Serious AEs
0.0%
Results posted
Jun 2023
Primary outcome: Primary: Acceptability: Client Satisfaction Questionnaire (CSQ) — 10.5 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Engage Prism (2.0) (Behavioral)
Age
Adult, Older Adult · 60+ yrs
Sex
All
Sponsor
Weill Medical College of Cornell University
Primary completion
Sep 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Acceptability: Client Satisfaction Questionnaire (CSQ)
9
PRIMARY
Acceptability: Client Satisfaction Questionnaire (CSQ)
9
PRIMARY
Feasibility: Client Enrollment
8
SECONDARY
Hamilton Depression Rating Scale
0.5
SECONDARY
Hamilton Depression Rating Scale
0.5

Summary

The primary aim in this pilot project is to test the feasibility, acceptability and impact (decreased depressive symptoms) of a brief behavioral treatment for depression (Engage) combined with video social support (PRISM 2.0) among socially isolated/lonely case management clients who endorse depressive symptoms. Eligible participants will be offered the combination of Engage and Prism 2.0, called Engage-Prism. The investigators hypothesize that the intervention (Engage Therapy With Video Support) will be accepted by participants, improve depressive symptom, and be feasible to complete.

Eligibility Criteria

Inclusion Criteria

  • Age at least 60 years
  • English speaking
  • Currently enrolled in case management at in 2 included agencies
  • Major depression on the SCID
  • 24-item Hamilton Depression Rating Scale (HAM-D) ≥ 19

Exclusion Criteria

  • Psychotic depression by SCID-V, i.e. presence of delusions
  • High suicide risk, i.e. intent or plan to attempt suicide in the near future
  • Presence of any Axis I psychiatric disorder
  • Presence of substance abuse other than unipolar major depression
  • History of psychiatric disorders, hypomania, are excluded
  • Acute or severe medical illness, i.e. delirium, metastatic cancer, decompensated cardiac, liver, or kidney failure, major surgery, stroke, or myocardial infarction during the three months prior to entry; or drugs often causing depression, e.g. steroids, reserpine, alpha- methyl-dopa, tamoxiphen, vincristine
  • Current involvement in psychotherapy
  • Cognitive impairment (i.e. telephone administered MoCA < 11)
  • Currently dwelling in non-community dwelling (e.g. prison, nursing home)
  • Hearing that would not allow participants to complete sessions with the RA/therapist
  • Vision impairment that would not allow the participant to use the study provided tablet
  • Inability to speak English
  • Aphasia interfering with communication
  • Literacy -assessed by reading a paragraph designed for those at 6th grade reading level
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05346055). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search